Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
口服小分子胰高血糖素樣肽-1受體激動劑 Danuglipron 在第2型糖尿病患者血糖控制中的療效和安全性：一項隨機臨床試驗。
JAMA Netw Open 2023-05-25
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
GLP-1受體激動劑在減重和安全性方面的差異：來自調節期的非隨機多中心研究。
Prim Care Diabetes 2023-08-01
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Orforglipron (LY3502970)，一種新型口服非肽類葡萄糖樣肽-1受體激動劑：針對2型糖尿病患者的第1b期、多中心、盲標、安慰劑對照、隨機、多劑量升級研究。
Diabetes Obes Metab 2023-08-03
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
口服小分子胰高血糖素樣肽-1受體激動劑danuglipron在2型糖尿病中的耐受性、安全性和藥效動力學：一項為期12週的隨機、安慰劑對照、2期研究，比較不同劑量逐步增加方案。
Diabetes Obes Metab 2023-09-05
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Retatrutide，一種針對2型糖尿病患者的GIP、GLP-1和葡萄糖素受體激動劑：在美國進行的隨機、雙盲、安慰劑和活性對照、平行組、2期試驗。
Lancet 2023-08-14
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
新型口服小分子 GLP-1 受體激動劑 orforglipron 和 danuglipron 在治療第2型糖尿病和肥胖方面的安全性和有效性：隨機對照試驗的系統性回顧和荟萃分析。
Metabolism 2023-11-29
Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
HRS-7535，一種新型口服小分子胰高血糖素樣肽-1受體激動劑，在健康受試者中的安全性、藥物動力學和藥效學：一項階段1、隨機、雙盲、安慰劑對照、單一和多重遞增劑量、以及食物影響試驗。
Diabetes Obes Metab 2024-02-06
A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity.
一項隨機的第一階段研究，探討新型神經肽 Y 受體 2 激動劑 BI 1820237 單獨或與低劑量 liraglutide 共同使用於其他健康的超重或肥胖男性中的效果。
Diabetes Obes Metab 2024-10-07